机器学习揭示非小细胞肺癌免疫治疗应答的PD-L1非依赖性基因表达上下文预测
该研究在IV期NSCLC诊断活检中,用NanoString nCounter检测770个免疫相关基因,基于55例训练队列构建监督机器学习模型,并在两个独立队列(n=67)中验证。模型预测的获益与PD-L1免疫组化表达正交,联合PD-L1阳性可识别高度 favorable 结局的患者,多因素分析证实独立性。
要点
- 基于免疫相关基因表达上下文的机器学习模型可预测NSCLC免疫治疗应答。
- 模型预测信息与PD-L1免疫组化表达正交,联合PD-L1可识别高度 favorable 结局。
- 7基因上下文的预测优于任何单一基因。
核心结论
- 利用上下文敏感检测和生物信息学捕获肿瘤免疫上下文,可精准预测NSCLC对PD-1/PD-L1导向免疫治疗的应答。
研究设计与样本
- 在来自两个胸科肿瘤中心的IV期NSCLC诊断活检FFPE样本中,用NanoString nCounter检测770个免疫相关基因和对照基因。
- 采用监督机器学习方法进行特征选择和预测模型构建,训练队列为55例接受PD-1/PD-L1抗体治疗的复发NSCLC患者。
- 模型在两个后续招募的独立患者队列(n=67)中验证。
主要发现
- 模型识别的免疫治疗优效患者在两个独立队列中得到验证(n=67,风险比=0.46,p=0.035)。
- 模型预测信息与PD-L1免疫组化表达正交:PD-L1阳性联合模型预测可识别高度 favorable 结局的患者。
- 多因素分析证实PD-L1阳性与模型预测的独立性。
- 模型可视化显示整个7基因上下文的预测优于任何单一基因。
关键数值与推荐
- 训练队列55例接受PD-1/PD-L1抗体治疗的复发NSCLC患者。
- 验证队列n=67,风险比=0.46,p=0.035。
临床怎么用
- 在NSCLC诊断活检中检测免疫相关基因表达上下文,结合机器学习模型可辅助预测PD-1/PD-L1免疫治疗应答。
- 模型预测与PD-L1免疫组化互补,联合PD-L1阳性可识别高度 favorable 结局的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current predictive biomarkers for PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1)-directed immunotherapy in non-small cell lung cancer (NSCLC) mostly focus on features of tumour cells. However, the tumour microenvironment and immune context are expected to play major roles in governing therapy response. Against this background, we set out to apply context-sensitive feature selection and machine learning approaches on expression profiles of immune-related genes in diagnostic biopsies of patients with stage IV NSCLC. METHODS: RNA expression levels were determined using the NanoString nCounter platform in formalin-fixed paraffin-embedded tumour biopsies obtained during the diagnostic workup of stage IV NSCLC from two thoracic oncology centres. A 770-gene panel covering immune-related genes and control genes was used. We applied supervised machine learning methods for feature selection and generation of predictive models. RESULTS: Feature selection and model creation were based on a training cohort of 55 patients with recurrent NSCLC treated with PD-1/PD-L1 antibody therapy. Resulting models identified patients with superior outcomes to immunotherapy, as validated in two subsequently recruited, separate patient cohorts (n = 67, hazard ratio = 0.46, p = 0.035). The predictive information obtained from these models was orthogonal to PD-L1 expression as per immunohistochemistry: Selecting by PD-L1 positivity at immunohistochemistry plus model prediction identified patients with highly favourable outcomes. Independence of PD-L1 positivity and model predictions were confirmed in multivariate analysis. Visualisation of the models revealed the predictive superiority of the entire 7-gene context over any single gene. CONCLUSION: Using context-sensitive assays and bioinformatics capturing the tumour immune context allows precise prediction of response to PD-1/PD-L1-directed immunotherapy in NSCLC.
引用
- Wiesweg M, Mairinger F, Reis H, et al. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. Eur J Cancer. 2020. PMID: 33059196. doi:10.1016/j.ejca.2020.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。